MCKESSON CORP

Discover how McKesson’s data‑driven logistics, value‑based pricing, and strong ROE deliver >100% gains, improve patient care, and drive shareholder value in a changing healthcare market.

SEC filings reveal Mckesson Corp’s executive equity holdings and a 301‑share sale, showing transparent governance and long‑term incentive alignment for investors.

Discover how MCKESSON CORP’s 2022 RSU plan boosts board stability and long‑term shareholder value in industrial automation.

Munro Concentrated Global Growth Fund outperformed MSCI World in June 2026, driven by AI‑chip leaders like NVIDIA and TSMC, while noting U.S. concentration risks and emerging edge‑AI opportunities.

McKesson’s pivot to digital health—leveraging its pharma logistics with AI‑powered RPM, CDSS, and data‑broker services—offers a 33% digital revenue boost amid rising regulatory and competitive challenges.

CEO Tyler Brian S. bought 12.5 M McKesson shares via a 10(b)(5) plan, adding to 10 M shares in the company’s 401(k) – a compliance‑focused SEC filing that shows executive confidence but not strategic change.

McKesson’s June 2026 SEC filings reveal stable executive ownership, compliant RSU grants and modest share‑price growth, underscoring its conservative equity strategy.

Explore how MCKESSON CORP’s minor weighting in Munro‑managed ETFs influences portfolio dynamics and investor insights.

McKesson’s May 2026 filings show executive RSU sales and Rule 144 compliance, highlighting strong governance, shareholder alignment, and transparency for investors and healthcare stakeholders.

McKesson Corp’s hospitality division sees 15% RevPAR gains, 7.2% occupancy rise, and cost cuts via smart refurbishments—boosting profits while keeping leverage low.